Journal
PROSTATE INTERNATIONAL
Volume 4, Issue 2, Pages 37-42Publisher
ELSEVIER INC
DOI: 10.1016/j.prnil.2016.05.001
Keywords
Castration Resistant; Drugs; Drug Therapy; Investigational Prostatic Neoplasm
Categories
Ask authors/readers for more resources
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms. Copyright (C) 2016 Asian Pacific Prostate Society, Published by Elsevier.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available